Wyeth

bought by pfizer

<p><b>Pfizer Inc</b> is the world's largest <a href="http://www.sourcewatch.org/index.php/Pharmaceutical_industry" title="Pharmaceutical industry">pharmaceuticals corporation</a>.

Brand names Viagra, Celebrex, Norvasc, and Lipitor. The company also

manufactures animal care products such as Revolution, an anti-parasitic.

In 2009, <a href="http://www.sourcewatch.org/index.php/Pfizer" title="Pfizer" class="mw-redirect">Pfizer</a> acquired its rival Wyeth for 68 billion dollars.<sup id="cite_ref-0" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-0">[1]</a></sup> Wyeth's over the counter brands included Advil, Centrum, Robitussin and ChapStick.<sup id="cite_ref-1" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-1">[2]</a></sup> The majority of its sales are conducted through the whole sale companies McKesson and Cardinal Health. <sup id="cite_ref-2" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-2">[3]</a></sup> See also complete listing of the company's prescription drugs. <sup id="cite_ref-3" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-3">[4]</a></sup>

In 2010, Pfizer had a total revenue of $67.81 billion<sup id="cite_ref-4" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-4">[5]</a></sup> Its CEO, Ian Read, had an annual compensation of $17.4 million the same year.</p>

<h2> <span class="mw-headline" id="Connection_to_the_American_Legislative_Exchange_Council">Connection to the American Legislative Exchange Council</span></h2>

<p>Michael Hubert, Vice President for "Leadership Communications," is

Pfizer's representative on ALEC's corporate board, as of 2011.

Furthermore, Pfizer was a "Vice Chairman" level sponsor of 2011 ALEC

Annual Conference,<sup id="cite_ref-5" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-5">[6]</a></sup><sup id="cite_ref-6" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-6">[7]</a></sup>

A list of <a href="http://www.sourcewatch.org/index.php/ALEC_Corporations" title="ALEC Corporations">ALEC corporations can be found here</a>.</p>

<p style="margin:3px; background:#2966B8; font-size:140%; font-weight:bold; border:1px solid #407FD4; text-align:left; color:#ffffff; padding:0.2em 0.4em;">About ALEC</p>

</th></tr><tr><td style="color:#000000;">

is a corporate bill mill. It is not just a lobby or a front group; it

is much more powerful than that. Through ALEC, corporations hand state

legislators their wishlists to benefit their bottom line. Corporations

fund almost all of ALEC's operations. They pay for a seat on ALEC task

forces where corporate lobbyists and special interest reps vote with

elected officials to approve “model” bills. Learn more at the Center for

Media and Democracy's <a rel="nofollow" class="external text" href="http://alecexposed.org/">ALECexposed.org</a>, and check out breaking news on our <a rel="nofollow" class="external text" href="http://www.PRWatch.org">PRWatch.org site</a>.</div>

</td></tr></tbody></table>

<h2> <span class="mw-headline" id="Overview.26_history.28subsection.29">Overview & history (subsection)</span></h2>

<p>See also <a href="http://www.sourcewatch.org/index.php/History_of_Pfizer" title="History of Pfizer">History of Pfizer</a>.</p>

<h2> <span class="mw-headline" id="Lobbying">Lobbying</span></h2>

<p>Pfizer spent $10,740,000 on <a href="http://www.sourcewatch.org/index.php/Lobbying" title="Lobbying">lobbying</a> in 2010. $2,120,000 of this amount went to 17 outside firms with the remainder being spent using in-house lobbyists. <sup id="cite_ref-7" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-7">[8]</a></sup>

According to Holly Bailey of <i>Open Secrets</i>:

"Over the last two years, Pfizer has been waging a legal battle to extend its patent on the epilepsy drug, <a href="http://www.sourcewatch.org/index.php/Neurontin" title="Neurontin">Neurontin</a>,

and in its merger with Pharmacia, the company will gain access to

dozens of new drugs whose patents expire in coming years. Even before

its announced merger, Pfizer was among the most aggressive in the

industry when it comes to fending off legislation that would seemingly

make patent laws more lax, claiming that such legislation would curb the

industry’s research and development into drugs that could cure rare

diseases.<sup id="cite_ref-8" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-8">[9]</a></sup></p>

<dl><dd>To make that argument, Pfizer has retained some of the Washington’s best known lobbyists, including former Reps. <a href="http://www.sourcewatch.org/index.php/Bill_Paxon" title="Bill Paxon">Bill Paxon</a> (R-N.Y.) and Norman Lent (R-N.Y.) and former Sen. <a href="http://www.sourcewatch.org/index.php/Dennis_DeConcini" title="Dennis DeConcini">Dennis DeConcini</a> (R-Ariz.). The company also retains <a href="http://www.sourcewatch.org/index.php/Scott_Hatch" title="Scott Hatch" class="mw-redirect">Scott Hatch</a>, son of Sen. <a href="http://www.sourcewatch.org/index.php/Orrin_Hatch" title="Orrin Hatch" class="mw-redirect">Orrin Hatch</a>

(R-Utah), who authored the drug patent law that remains in effect

today. Since 1997, Pfizer has reported nearly $20 million in lobbying

expenditures, according to the <a href="http://www.sourcewatch.org/index.php/Secretary_of_the_Senate" title="Secretary of the Senate">Secretary of the Senate</a>. (Pharmacia spent $13.4 million during the same period.)" <sup id="cite_ref-9" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-9">[10]</a></sup></dd></dl>

<h2> <span class="mw-headline" id="Political_contributions">Political contributions</span></h2>

<p><a rel="nofollow" class="external text" href="http://www.opensecrets.org/orgs/totals.php?id=D000000138&cycle=2010">Open Secrets</a>

reports that in 2010, Pfizer gave $1,581,836 to candidates. $826,045

was given to federal Democratic candidates and $738,791 on federal

Republican candidates.

<a href="http://www.sourcewatch.org/index.php/Hank_McKinnell" title="Hank McKinnell" class="mw-redirect">Hank McKinnell</a>, then Chair & CEO of Pfizer, was a <a href="http://www.sourcewatch.org/index.php/Bush%27s_Rangers" title="Bush's Rangers">Bush Ranger</a> having raised at least $200,000 for <a href="http://www.sourcewatch.org/index.php/George_Walker_Bush" title="George Walker Bush">Bush</a> in the <a href="http://www.sourcewatch.org/index.php/U.S.presidential_election,2004" title="U.S. presidential election, 2004">2004 presidential election</a>. <sup id="cite_ref-10" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-10">[11]</a></sup>

Pfizer gave $2,865,575 dollars to federal candidates in the 2008 election cycle through its <a href="http://www.sourcewatch.org/index.php/Political_action_committee" title="Political action committee">political action committee</a> (PAC) - 50% to <a href="http://www.sourcewatch.org/index.php/Democrats" title="Democrats" class="mw-redirect">Democrats</a> and 50% to <a href="http://www.sourcewatch.org/index.php/Republican_Party_%28USA%29" title="Republican Party (USA)">Republicans</a>. <sup id="cite_ref-11" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-11">[12]</a></sup>

Pfizer was among several companies giving record political

contributions four years after a law was passed attempting to reduce the

impact of corporate money in U.S. politics. According to <i>Bloomberg</i>:</p>

<dl><dd>"The companies are working around the law, which banned unlimited

contributions to parties, by giving more money through their political

action committees than ever before in the first year of an election

cycle, and writing checks to loosely regulated independent groups,

financial disclosures show." <sup id="cite_ref-12" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-12">[13]</a></sup></dd></dl>

<h3> <span class="mw-headline" id="Pfizer_and_health_care_reform">Pfizer and health care reform</span></h3>

<p>In January of 2006, Pfizer, through its public affairs agency <a href="http://www.sourcewatch.org/index.php/Spectrum_Science_Communications" title="Spectrum Science Communications">Spectrum Science</a>,

hoped to, "open dialogue about, and ultimately reform, the nation's

health care system." Spectrum started organizing the "Ceasefire on

Health Care" town meetings for Pfizer in June 2005. The idea, originated

from former U.S. Senator <a href="http://www.sourcewatch.org/index.php/John_Breaux" title="John Breaux">John Breaux</a>. According to Spectrum's director of public affairs, Claire Barnard:</p>

<dl><dd>"The thrust of the campaign ... is to make incremental changes. I

think the public is really yearning for this. I think people are tired

of turning on the TV and seeing all the name calling."</dd></dl>

<p>The "Ceasefire on Health Care" town meetings are funded by Pfizer and <a href="http://www.sourcewatch.org/index.php/American_University" title="American University">American University</a>. They have featured Senator <a href="http://www.sourcewatch.org/index.php/Hillary_Rodham_Clinton" title="Hillary Rodham Clinton">Hillary Clinton</a> and former Congressman <a href="http://www.sourcewatch.org/index.php/Newt_Gingrich" title="Newt Gingrich">Newt Gingrich</a>. C-Span has covered the events, which have been held at the <a href="http://www.sourcewatch.org/index.php/Brookings_Institution" title="Brookings Institution">Brookings Institution</a>, <a href="http://www.sourcewatch.org/index.php/Heritage_Foundation" title="Heritage Foundation">Heritage Foundation</a> and <a href="http://www.sourcewatch.org/index.php/National_Press_Club" title="National Press Club">National Press Club</a>. <sup id="cite_ref-13" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-13">[14]</a></sup></p>

<h2> <span class="mw-headline" id="Corporate_Accountability">Corporate Accountability</span></h2>

<p>Shareholders may attend and vote in annual meetings and add items to

the agenda. They may also nominate candidates for board member

elections. There are no exceptions to the one share, one vote principle.

Pfizer has initiated a series of reforms to improve shareholder

control, including annual elections for all directors.<sup id="cite_ref-14" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-14">[15]</a></sup></p>

<h3> <span class="mw-headline" id="Stakeholder_engagement">Stakeholder engagement</span></h3>

<p>Pfizer has two stakeholder specific engagement policies: <i>Pfizer’s Global Policy on Interactions with Healthcare Professionals</i> and <i>Pfizer Principles for Working in Partnership with Patient Advocacy Groups</i>.

Both identify key principles that should underpin engagement with

health care professionals and Patient advocacy groups, respectively.

Both make a commitment to being open about how shareholders affect

decisions, but they do not identify when shareholders may participate in

company decisions. Furthermore, there is no assurance that Pfizer will

change policy as a result of stakeholder wishes (or even provide

explanations). The two policies are overseen by a number of senior

executives. The <i>Global Policy on Interaction with Healthcare Professionals</i>

is overseen by multiple senior executives. It covers global marketing,

research and development; and global business conduct. The Vice

President of <i>Global Alliance Development</i> and the Senior VP of <i>Philanthropy and Stakeholder Advocacy</i>, oversee Pfizer’s <i>Principles of Working in Partnerships with Patient Advocacy Groups</i>.

Each policy is disseminated through multiple mediums and translated

into at least 20 languages. Pfizer does not provide training for staff

on stakeholder engagement issues. Also, Pfizer has not institutionalized

external stakeholder engagement in corporate decision-making. The

company created a <i>Worldwide Public Affairs and Policy department</i>

dedicated to philanthropy and shareholder advocacy, which solicits

feedback from stakeholders. However, shareholders do not participate

directly in any committee or group.</p>

<h3> <span class="mw-headline" id="Human_rights">Human rights</span></h3>

<p>Pfizers Corporate Equality Index Rating from Human Rights Watch for 2006 was 100.<sup id="cite_ref-15" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-15">[16]</a></sup></p>

<h2> <span class="mw-headline" id="Social_responsibility_initiatives">Social responsibility initiatives</span></h2>

<p>In 2001, Pfizer announced that it will provide an unlimited free

supply of Diflucan, a drug that combats fungal infections associated

with AIDS, to 50 of the world’s poorest countries. Previously, Pfizer

had conducted a successful pilot program in South Africa. The patent on

Diflucan expired in 2004. <sup id="cite_ref-16" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-16">[17]</a></sup></p>

<h2> <span class="mw-headline" id="Public_relations">Public relations</span></h2>

<h3> <span class="mw-headline" id="Strategy">Strategy</span></h3>

<p>In the wake of a CEO change in 2006, Pfizer changed the name of its

corporate affairs practice to public affairs, in order to "better

reflect the increasing importance of influencing public policy and

opinion to the company's success." The change was described as, "a

larger reorganization of Pfizer's management structure," that included <a href="http://www.sourcewatch.org/index.php/Jeff_Kindler" title="Jeff Kindler">Jeff Kindler</a>'s promotion from head of corporate affairs to CEO:</p>

<dl><dd>"Rich Bagger will head Pfizer's new worldwide public affairs and

policy division, which previously had been called the corporate affairs

division." In that role, Bagger will oversee "public policy development,

government relations, communications, media, philanthropy, and

stakeholder advocacy." <sup id="cite_ref-17" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-17">[18]</a></sup></dd></dl>

<p>According to a memo from the new CEO to employees, the changes would

help Pfizer make decisions more quickly, an important goal, as "patients

and their families are using newly available information to take more

control over their health care decisions." <sup id="cite_ref-18" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-18">[19]</a></sup></p>

<h3> <span class="mw-headline" id="Americans_for_Medical_Progress">Americans for Medical Progress</span></h3>

<p>Pfizer personnel sit on the board of AMP. See also <a href="http://www.sourcewatch.org/index.php/Americans_for_Medical_Progress" title="Americans for Medical Progress">Americans for Medical Progress</a>.</p>

<h2> <span class="mw-headline" id="Drug_controversies">Drug controversies</span></h2>

<h3> <span class="mw-headline" id="Lipitor_ads">Lipitor ads</span></h3>

<p>In September 2008, Pfizer resumed advertising for its cholesterol drug <a href="http://www.sourcewatch.org/index.php/Lipitor" title="Lipitor">Lipitor</a>. In February 2008, the drugmaker pulled its Lipitor ads, over charges <a rel="nofollow" class="external text" href="http://www.prwatch.org/node/7051">they were misleading</a>.

The old ads featured artificial heart inventor Robert Jarvik, who

appeared to be giving medical advice though he isn't a practicing

physician. The new ads feature "John E.," a baby boomer and heart-attack

survivor who "didn't take a cholesterol-fighting drug before his heart

attack ... despite a history of high cholesterol." A Pfizer marketing

executive said, "When we did testing with consumers ... John really

resonated with them." Pfizer is eager to maximize sales before its

patent on Lipitor ends in 2011. <sup id="cite_ref-19" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-19">[20]</a></sup></p>

<h3> <span class="mw-headline" id="Celebrex">Celebrex</span></h3>

<p>In November 2004 <a href="http://www.sourcewatch.org/index.php/Ogilvy_Public_Relations_Worldwide" title="Ogilvy Public Relations Worldwide">Ogilvy Public Relations Worldwide</a>, part of the <a href="http://www.sourcewatch.org/index.php/WPP_Group" title="WPP Group" class="mw-redirect">WPP Group</a>;

took over accounts for Pfizer's Celebrex and Bextra pain medications.

In December of 2004, a report linked high doses of Celebrex (a member of

the class of drugs referred to as Cox-2 inhibitors) to increased risk

of heart attacks.<sup id="cite_ref-20" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-20">[21]</a></sup> The co-managing director of the <a href="http://www.sourcewatch.org/index.php/WPP" title="WPP">WPP</a> Group's health and medical practice, Sherry Pudloski, told <i>O'Dwyer's PR Daily</i> that they still held the account, but would not elaborate on what they did for the company. <sup id="cite_ref-21" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-21">[22]</a></sup></p>

<h3> <span class="mw-headline" id="Off-label_promotional_practices_.28Neurontin.29">Off-label promotional practices (Neurontin)</span></h3>

<p>Access to pharmaceutical industry documents in 2006 revealed marketing strategies used to promote Neurontin for off-label use. <sup id="cite_ref-22" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-22">[23]</a></sup> In 1993, the US <a href="http://www.sourcewatch.org/index.php/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">Food and Drug Administration</a>

(FDA) approved gabapentin (Neurontin®, Pfizer) only for treatment of

seizures. Warner-Lambert, which merged with Pfizer in 2000, used

activities not usually associated with sales promotion. This included

continuing medical education and research, sponsored articles about the

drug for medical literature and alleged suppression of unfavorable study

results, to promote gabapentin. Within 5 years, the drug was being

widely used for the off-label treatment of pain and psychiatric

conditions. In 2004, Warner-Lambert admitted to violating FDA

regulations by promoting the drug for pain, psychiatric conditions,

migraines and other unapproved uses. The company paid $430 million to

resolve criminal and civil health care liability charges.<sup id="cite_ref-23" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-23">[24]</a></sup>, <sup id="cite_ref-24" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-24">[25]</a></sup></p>

<h3> <span class="mw-headline" id="Diflucan_.28fluconazole.29">Diflucan (fluconazole)</span></h3>

<p>Pfizer has been involved in controversies over the medicine Diflucan

(generic name fluconazole). In 1998, a campaign by Thai public health

groups led to the elimination of the Pfizer monopoly on selling

fluconazole in Thailand. Subsequently, the price decreased from 200 baht

to 6.5 baht in nine months. Faced with pressure for compulsory licenses

to the Pfizer patent on this drug, the company later established a

program for limited access to the medicine in Africa. <sup id="cite_ref-25" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-25">[26]</a></sup></p>

<h3> <span class="mw-headline" id="Antivirals.28Viracept.26_Maraviroc.29">Antivirals (Viracept & Maraviroc)</span></h3>

<p>Drugs used to treat HIV and AIDS are various classes of toxic

chemotherapies known as "antivirals" or "antiretrovirals". AIDS drugs

manufactured by Pfizer include Viracept (protease inhibitor), Maraviroc

and Maraviroc Rescriptor (entry inhibitors).<sup id="cite_ref-26" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-26">[27]</a></sup> See also <a href="http://www.sourcewatch.org/index.php/AIDS_industry" title="AIDS industry">AIDS industry</a>.

According to company information, in the U.S., 46% of all new

HIV/AIDS cases occur in the South. From 2003 to 2006, the Pfizer

Foundation funded 23 innovative HIV/AIDS prevention programs and

strengthened the capacity of community-based organizations to reach and

serve their communities.<sup id="cite_ref-27" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-27">[28]</a></sup>

Since 2003, the company has committed a $3 million dollar grant

supporting a southern HIV/AIDS prevention (by way of Pfizer

pharmaceuticals). However, according to he <a rel="nofollow" class="external text" href="http://www.eatg.org">European AIDS Treatment Group (EATG)</a>, collection of activists from 31 European countries:</p>

<dl><dd>"The design of the trial for Pfizer's CCR5 inhibitor Maraviroc

(previously known as UK-427,857) is putting people with HIV infection at

unnecessary risk of developing AIDS."<sup id="cite_ref-28" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-28">[29]</a></sup></dd></dl>

<p>On June 20, 2007 Maraviroc was received a letter of approval from the <a href="http://www.sourcewatch.org/index.php/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">Food and Drug Administration</a> (FDA) advisory board. The letter was a product of expedited review of the novel HIV compound.</p>

<h3> <span class="mw-headline" id="Premarin">Premarin</span></h3>

<div class="thumbcaption">The Bitter Truth about Premarin. - United Animal Nations</div>

</div>

<h4> <span class="mw-headline" id="Premarin_.26_PMU_ranches">Premarin & PMU ranches</span></h4>

<p><a href="http://www.sourcewatch.org/index.php/Premarin" title="Premarin">Premarin</a>

was approved by the USDA in 1942 for manufacture by Wyeth (now Pfizer).

Premarin, a drug derived from pregnant mares’ urine (PMU), is

prescribed for "symptoms of menopause". The urine is collected from

mares confined in barns on over 70 "PMU ranches" in the United States

and Canada. Despite the availability of humane and safer alternatives,

Premarin is among the most widely prescribed and profitable drugs in

America. The industry is "self-regulated through manufacturer <a href="http://www.sourcewatch.org/index.php/Pfizer" title="Pfizer" class="mw-redirect">Pfizer</a>’s

Code of Practice". Mares in Premarin production commonly suffer from

abrasions, leg swelling, excessive boredom, stress, and early death.

Strapped to urine collection bags six months out of the year; they are

tied to stalls too narrow to turn around or lie down in and are denied

free access to water. There is no minimum code of practice for exercise

or even that they be exercised at all. <sup id="cite_ref-29" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-29">[30]</a></sup></p>

<h5> <span class="mw-headline" id="Studies_of_Premarin_health_risks">Studies of Premarin health risks</span></h5>

<p>Premarin has been classified as a "dangerous drug" and the number one most likely to cause disability or other serious outcome. <sup id="cite_ref-30" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-30">[31]</a></sup> Premarin increases risks of uterine cancer, heart attacks, strokes, breast cancer and blood clots. <sup id="cite_ref-31" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-31">[32]</a></sup>, <sup id="cite_ref-32" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-32">[33]</a></sup>

See also <a href="http://www.sourcewatch.org/index.php/Premarin" title="Premarin">Premarin</a>.</p>

<h2> <span class="mw-headline" id="Global_drug_issues">Global drug issues</span></h2>

<h3> <span class="mw-headline" id="Nigeria">Nigeria</span></h3>

<p>In May 2006, the <a href="http://www.sourcewatch.org/index.php/Washington_Post" title="Washington Post">Washington Post</a>

published a Nigerian government report that had remained unreleased for

five years. In this report, a panel of Nigerian medical experts found

that Pfizer violated international law, stemming from the company's

alleged testing of an unapproved, oral form of <a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Trovafloxacin">Trovafloxacin</a>, on children with <a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Trovafloxacin">meningitis</a> in Nigeria.

According to Pfizer, they conducted the trial with full knowledge of the Nigerian government.<sup id="cite_ref-33" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-33">[34]</a></sup> These allegations <a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Kano_Trovafloxacin_trial_litigation">have been</a>

the subject of litigation in both America and Nigeria. On June 5, 2007

the Nigerian government filed a civil lawsuit for $7 billion in damages

against Pfizer, in relation to the experimental meningitis treatment

given to children. <sup id="cite_ref-34" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-34">[35]</a></sup>.

Two hundred children received Trovan in Kano, Nigeria, in 1996,

according to Pfizer. The Nigerian and Kano state governments alleged

that the antibiotic was administered without parental consent and that

it disabled or killed some children. <sup id="cite_ref-35" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-35">[36]</a></sup>

In July 2007, the Nigerian government filed criminal charges against Pfizer over the trials. <sup id="cite_ref-36" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-36">[37]</a></sup>

In turn, Pfizer hired investigators to unearth embarrassing information

about Nigeria's attorney general Michael Aondoakaa, in hopes that the

charges would be dropped.<sup id="cite_ref-37" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-37">[38]</a></sup></p>

<h3> <span class="mw-headline" id="Philippines">Philippines</span></h3>

<p>In March of 2006, Pfizer sued the Philippine government and

government health officials, to prevent Philippine drug regulators from

allowing the importation of less expensive versions of a Pfizer heart

disease drug. <sup id="cite_ref-38" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-38">[39]</a></sup></p>

<h3> <span class="mw-headline" id="Brazil">Brazil</span></h3>

<p>In 2001, Pfizer requested the U.S. government pressure the Brazilian

government against issuing compulsory licenses for the patents on the

AIDS drug nelfinavir.</p>

<h3> <span class="mw-headline" id="Thailand">Thailand</span></h3>

<p>In 1998, the Thai government acquiesced to requests by public health

groups and eliminated Pfizer’s monopoly on fluconazole, a leading AIDS

drug, reducing the price of the drug from 200 baht to 6.5 baht within a

year. <sup id="cite_ref-39" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-39">[40]</a></sup></p>

<h2> <span class="mw-headline" id="Clinical_trials">Clinical trials</span></h2>

<h3> <span class="mw-headline" id="Toxic_drug_trials_on_foster_children">Toxic drug trials on foster children</span></h3>

<p>See also <a href="http://www.sourcewatch.org/index.php/Foster_child_drug_trials" title="Foster child drug trials">Foster child drug trials</a>.</p>

<h2> <span class="mw-headline" id="Animal_testing">Animal testing</span></h2>

<p>Pfizer does <a href="http://www.sourcewatch.org/index.php/Animal_testing" title="Animal testing">animal testing</a>.</p>

<h4> <span class="mw-headline" id="Facility_information.2C_progress_reports_.26_USDA-APHIS_reports">Facility information, progress reports & USDA-APHIS reports</span></h4>

<p>For links to copies of a facility's <a href="http://www.sourcewatch.org/index.php/U.S._Department_of_Agriculture" title="U.S. Department of Agriculture">U.S. Department of Agriculture</a> (USDA)-Animal Plant Health Inspection (APHIS) reports, other information and links, see also <a rel="nofollow" class="external text" href="http://www.all-creatures.org/saen/res-fr.html">Stop Animal Experimentation NOW!: Facility Reports and Information</a>.

This site contains listings for all 50 states, links to biomedical

research facilities in that state and PDF copies of government documents

where facilities must report their animal usage. (Search: Pfizer, Inc.,

New York, New York; Wyeth, Philadelphia, Pennsylvania; Wyeth Vaccines,

Marietta, PA; Fort Dodge Laboratories, Fort Dodge, Iowa.)

This facility performed animal experiments involving pain or distress

but no analgesics, anesthetics or pain relievers were administered. For

links to copies of this facility's USDA-APHIS reports, other

information and links, see also Facility Reports & Information: Fort

Dodge Animal Health, Monmouth Junction, New Jersey.<sup id="cite_ref-40" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-40">[41]</a></sup>

This facility performed animal experiments involving pain or distress

but no analgesics, anesthetics or pain relievers were administered. For

copies of this facility's USDA-APHIS reports, other information and

links, see also Facility Reports & Information, Pfizer, Inc., White

Hall, IL. <sup id="cite_ref-41" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-41">[42]</a></sup></p>

<h4> <span class="mw-headline" id="USDA_AWA_reports">USDA AWA reports</span></h4>

<p>As of May 26, 2009, the USDA began posting all inspection reports for

animal breeders, dealers, exhibitors, handlers, research facilities and

animal carriers by state. See also <a rel="nofollow" class="external text" href="http://www.aphis.usda.gov/animal_welfare/inspection_list.shtml">USDA Animal Welfare Inspection Reports</a>.</p>

<h4> <span class="mw-headline" id="Contract_testing">Contract testing</span></h4>

<p>Pfizer contract tests out to <a href="http://www.sourcewatch.org/index.php/Huntingdon_Life_Sciences" title="Huntingdon Life Sciences">Huntingdon Life Sciences</a> (HLS). <sup id="cite_ref-42" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-42">[43]</a></sup>

Hungtindon Life Sciences is the 3rd largest contract research

organization (CRO) in the world and the largest animal testing facility

in all of Europe. Firms hire HLS to conduct animal toxicity tests for

agrochemicals, petrochemicals, household products, pharmaceutical drugs

and toxins.HLS has a long history of gross animal welfare violations.

See also <a href="http://www.sourcewatch.org/index.php/Huntingdon_Life_Sciences" title="Huntingdon Life Sciences">Huntingdon Life Sciences</a>.

Pfizer also contract tests out to <a href="http://www.sourcewatch.org/index.php/SNBL" title="SNBL" class="mw-redirect">SNBL</a>, <sup id="cite_ref-43" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-43">[44]</a></sup> an international contract research organization (CRO). SNBL has a history of gross animal welfare violations. See also <a href="http://www.sourcewatch.org/index.php/SNBL" title="SNBL" class="mw-redirect">SNBL</a>.</p>

<h2> <span class="mw-headline" id="Leadership">Leadership</span></h2>

<ul><li><a href="http://www.sourcewatch.org/index.php?title=Ian_Read&action=edit&redlink=1" class="new" title="Ian Read (page does not exist)">Ian Read</a> - CEO - $17.4 million in 2010</li><li>Olivier Brandicourt - President & General Mgr, Primary Care</li><li>Frank D'Amelio - Executive VP, CFO - $6.5 million in 2010</li><li>Mikael Dolsten - President, Global R&D</li><li>Geno Germano - President & General Mgr, Specialty Care & Oncology</li><li>Chuck Hill - Executive VP, Global Human Resources</li><li>Doug Lankler - Executive VP, Chief Compliance Officer</li><li>Freda C. Lewis-Hall - Executive VP, Chief Medical Officer</li><li>Kristin Peck - Executive VP, Global Business Development</li><li>Cavan Redmond - Group President, Animal Health, Consumer Healthcare, Capsugel & Corporate Strategy</li><li>Amy Schulman - Executive VP, General Counsel & Business Unit Lead Nutritionals</li><li>David Simmons - President & General Mgr, Emerging Markets and Established Products</li><li>Sally Susman - Executive VP, Policy, External Affairs & Communications<sup id="cite_ref-44" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-44">[45]</a></sup></li></ul>

<h3> <span class="mw-headline" id="Former_executives">Former executives</span></h3>

<ul><li><a href="http://www.sourcewatch.org/index.php/Jeff_Kindler" title="Jeff Kindler">Jeff Kindler</a> - CEO</li><li><a href="http://www.sourcewatch.org/index.php/Hank_McKinnell" title="Hank McKinnell" class="mw-redirect">Hank McKinnell</a> - CEO</li><li><a href="http://www.sourcewatch.org/index.php/Robert_M._Amen" title="Robert M. Amen">Robert M. Amen</a> - former board member</li></ul>

<h3> <span class="mw-headline" id="Key_executives_.26_pay">Key executives & pay</span></h3>

<ul><li>Ian C. Read (57) - Chairman & CEO - $3.30 M</li><li>Frank A. D'Amello (53) - CFO & Senior VP, Bussiness Operations - $3.08 M</li><li>Freda C. Lewis-Hall (55) - Chief Medical Officer & Sr. VP of Executive Compliance Committee</li></ul>

<h3> <span class="mw-headline" id="Board_members">Board members</span></h3>

<ul><li>Dennis A. Ausiello</li><li>Michael S. Brown</li><li>M. Anthony Burns</li><li>Robert N. Burt</li><li>W. Don Cornwell</li><li>Frances D. Fergusson</li><li>William H. Gray III</li><li>Constance J. Horner</li><li>Suzanne Nora Johnson</li><li>James M. Kilts</li><li>George A. Lorch</li><li>John P. Mascotte</li><li>Ian C. Read</li><li>Stephen Sanger</li><li>William C. Steere, Jr.<sup id="cite_ref-46" class="reference"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_note-46">[47]</a></sup></li></ul>

<h2> <span class="mw-headline" id="Contact">Contact</span></h2>

<p>Pfizer

235 E. 42nd St.

New York, NY 10017

Phone: 212-573-2323

Fax: 212-573-7851

Web address: <a rel="nofollow" class="external free" href="http://www.pfizer.com">http://www.pfizer.com</a></p>

<h2> <span class="mw-headline" id="Articles_.26_sources">Articles & sources</span></h2>

<h3> <span class="mw-headline" id="SourceWatch_articles">SourceWatch articles</span></h3>

<ul><li><a href="http://www.sourcewatch.org/index.php/AIDS_industry" title="AIDS industry">AIDS industry</a></li><li><a href="http://www.sourcewatch.org/index.php/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a></li><li><a href="http://www.sourcewatch.org/index.php/Animal_testing" title="Animal testing">Animal testing</a></li><li><a href="http://www.sourcewatch.org/index.php/Consensus_Research_Group" title="Consensus Research Group">Consensus Research Group</a></li><li><a href="http://www.sourcewatch.org/index.php/Foster_child_drug_trials" title="Foster child drug trials">Foster child drug trials</a></li><li><a href="http://www.sourcewatch.org/index.php/Glover_Park_Group" title="Glover Park Group">Glover Park Group</a></li><li><a href="http://www.sourcewatch.org/index.php/Humane_Movement" title="Humane Movement">Humane Movement</a></li><li><a href="http://www.sourcewatch.org/index.php/Human_rights" title="Human rights">Human rights</a></li><li><a href="http://www.sourcewatch.org/index.php/National_Alliance_on_Mental_Illness" title="National Alliance on Mental Illness">National Alliance on Mental Illness</a> (NAMI)</li><li><a href="http://www.sourcewatch.org/index.php/National_Primate_Research_Center_System" title="National Primate Research Center System">National Primate Research Center System</a></li><li><a href="http://www.sourcewatch.org/index.php/Pfizer_Inc/stats,_details" title="Pfizer Inc/stats, details">Pfizer Inc/stats, details</a></li><li><a href="http://www.sourcewatch.org/index.php/Pfizer_Australia_Neuroscience_Research_Grants" title="Pfizer Australia Neuroscience Research Grants">Pfizer Australia Neuroscience Research Grants</a></li><li><a href="http://www.sourcewatch.org/index.php/Pharmaceutical_industry" title="Pharmaceutical industry">Pharmaceutical industry</a></li><li><a href="http://www.sourcewatch.org/index.php/SANE_Australia" title="SANE Australia">SANE Australia</a></li><li><a href="http://www.sourcewatch.org/index.php/Spectrum_Science_Communications" title="Spectrum Science Communications">Spectrum Science Communications</a></li><li><a href="http://www.sourcewatch.org/index.php/War_on_Animals" title="War on Animals">War on Animals</a></li><li><a href="http://www.sourcewatch.org/index.php/War_on_Cancer" title="War on Cancer">War on Cancer</a></li></ul>

<h3> <span class="mw-headline" id="References">References</span></h3>

<ol class="references"><li id="cite_note-0"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-0">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.hoovers.com/pfizer/--ID11175--/free-co-factsheet.xhtml">Company Description: Pfizer Inc</a>, Hoovers, accessed December 2009</span></li><li id="cite_note-1"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-1">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.hoovers.com/wyeth/--ID10093--/free-co-profile.xhtml">Wyeth</a>, Hoovers, accessed January 2009</span></li><li id="cite_note-2"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-2">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.hoovers.com/pfizer/--ID__11175--/free-co-factsheet.xhtml">Company Description: Pfizer Inc</a>, Hoovers, accessed December 2009</span></li><li id="cite_note-3"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-3">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.pfizer.com/pfizer/do/mn_prescription.jsp">Products</a>, Pfizer, accessed December 2009</span></li><li id="cite_note-4"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-4">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investing.businessweek.com/research/stocks/financials/financials.asp?ticker=PFE:US">Pfizer Annual Financials</a>,"Bloomberg BusinessWeek"</span></li><li id="cite_note-5"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-5">↑</a> <span class="reference-text">[American Legislative Exchange Council, 2011 Conference Sponsors, conference brochure on file with CMD, August 11, 2011]</span></li><li id="cite_note-6"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-6">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.alec.org/AM/Template.cfm?Section=Private_Enterprise_Board&Template=/CM/HTMLDisplay.cfm&ContentID=15553">ALEC Private Enterprise Board</a>, American Legislative Exchange Council. ALEC.org. Accessed Aug. 11, 2011.</span></li><li id="cite_note-7"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-7">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.opensecrets.org/lobby/clientsum.php?year=2010&lname=Pfizer+Inc&id=">Pfizer Inc lobbying expenses</a>, <i>Open Secrets</i>, accessed January 2011</span></li><li id="cite_note-8"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-8">↑</a> <span class="reference-text">Holly Bailey, <i>Prescription Drugs: A Look at Contributions from Pfizer & Pharmacia</i>, <i>Open Secrets</i>, July 18, 2002</span></li><li id="cite_note-9"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-9">↑</a> <span class="reference-text">Holly Bailey, <i>Prescription Drugs: A Look at Contributions from Pfizer & Pharmacia</i>, <i>Open Secrets</i>, July 18, 2002</span></li><li id="cite_note-10"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-10">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.tpj.org/docs/pioneers/pioneers_table.jsp">Pioneers and Rangers</a>, <i>Texans for Public Justice</i>, accessed August 2007.</span></li><li id="cite_note-11"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-11">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.opensecrets.org/pacs/lookup2.php?strID=C00016683&cycle=2008">2008 PAC Summary Data</a>, <i>Open Secrets</i>, accessed March 2010</span></li><li id="cite_note-12"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-12">↑</a> <span class="reference-text">Jonathan D. Salant, "<a rel="nofollow" class="external text" href="http://www.bloomberg.com/apps/news?pid=10000103&sid=as5eokD7VAys&refer=us">GM, Comcast, Pfizer Boost Political Giving, Skirt Federal Ban</a>", <i>Bloomberg</i>, February, 21, 2006.</span></li><li id="cite_note-13"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-13">↑</a> <span class="reference-text"><i>PR Week</i>, January 2006</span></li><li id="cite_note-14"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-14">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.oneworldtrust.org/?display=Pfizer">2006 GAR Corporate Accountability Profile: Pfizer</a>, One World Trust, 2006 (Search Pfizer)</span></li><li id="cite_note-15"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-15">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.hrc.org/issues/ceihome.asp">Corporate Equality Index</a>, Human Rights Campaign, 2006</span></li><li id="cite_note-16"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-16">↑</a> <span class="reference-text">Barbara Crossette <a rel="nofollow" class="external text" href="http://query.nytimes.com/gst/fullpage.html?res=9D06E3DE1E3FF934A35755C0A9679C8B63&n=Top/Reference/Times%20Topics/Organizations/U/United%20Nations">AIDS Fungus Drug Offered to Poor Nations</a>, New York Times, June 2001</span></li><li id="cite_note-17"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-17">↑</a> <span class="reference-text"><i>PR Week</i>, August 2006</span></li><li id="cite_note-18"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-18">↑</a> <span class="reference-text"><i>PR Week</i>, August 2006</span></li><li id="cite_note-19"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-19">↑</a> <span class="reference-text">Jon Kamp, "<a rel="nofollow" class="external text" href="http://online.wsj.com/article/SB122031942962189393.html">Pfizer Drops Celebrity Pitch in New Lipitor Spots: As Generics Catch Up, Dr. Jarvik Is Jettisoned From Heart-Drug Ads</a>," <i>Wall Street Journal</i> (sub req'd), September 2, 2008.</span></li><li id="cite_note-20"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-20">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.msnbc.msn.com/id/6727955/ns/health-arthritis/t/fda-urges-alternatives-celebrex/">FDA urges alternatives to Celebrex</a>,"MSNBC.com" 12/18/2004</span></li><li id="cite_note-21"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-21">↑</a> <span class="reference-text"><i>O'Dwyer's PR Daily</i>, 2004</span></li><li id="cite_note-22"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-22">↑</a> <span class="reference-text">Michael A. Steinman, MD; Lisa A. Bero, PhD; Mary-Margaret Chren, MD & C. Seth Landefeld, MD <a rel="nofollow" class="external text" href="http://annals.org/content/145/4/284.full">Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents</a>, Annals of Internal Medicine, Volume 145, Issue 4, pg. 284-293, 2006</span></li><li id="cite_note-23"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-23">↑</a> <span class="reference-text">Jane E. Henney, MD <a rel="nofollow" class="external text" href="http://www.annals.org/cgi/content/full/145/4/305">Safeguarding Patient Welfare: Who's In Charge?</a>, Annals of Internal Medicine, vol 145, no. 3, pp. 305-307, 2006</span></li><li id="cite_note-24"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-24">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm">Warner-Lambert to pay $430 million to resolve criminal and civil health care liability charges</a>, <a href="http://www.sourcewatch.org/index.php/U.S._Department_of_Justice" title="U.S. Department of Justice">U.S. Department of Justice</a> press release, accessed August 2006</span></li><li id="cite_note-25"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-25">↑</a> <span class="reference-text">Emelia Sithole <a rel="nofollow" class="external text" href="http://ww4.aegis.org/news/re/2001/RE010226.html">S. Africa okays Pfizer AIDS drug distribution</a>, Reuters, February 21, 2001</span></li><li id="cite_note-26"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-26">↑</a> <span class="reference-text">(Search brand names) <a rel="nofollow" class="external text" href="http://www.pfizer.com/pfizer/do/mn_prescription.jsp">Products</a>, Pfizer, accessed December 2009</span></li><li id="cite_note-27"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-27">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.pfizer.com/pfizer/subsites/philanthropy/caring/global.health.hiv.southern.jsp">Doing Business Responsibly</a>, Pfizer, accessed December 2009</span></li><li id="cite_note-28"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-28">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.aidsmeds.com/news/20050412ethc002.html">AidsMeds</a>, aidsmeds.com, 2005</span></li><li id="cite_note-29"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-29">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.aspca.org/fight-animal-cruelty/equine-cruelty/premarin.aspx">Premarin</a>, American Society for the Prevention of Cruelty to Animals, accessed January 2011</span></li><li id="cite_note-30"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-30">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.injuryboard.com/topic/Premarin.aspx">Premarin</a>, Injury Board, Sept 2007</span></li><li id="cite_note-31"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-31">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=Pre1347.html&contentName=Premarin&contentId=455">Prescription Drugs: Premarin</a>, PDR Health, accessed August 2009</span></li><li id="cite_note-32"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-32">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.drugs.com/pro/premarin.html">Premarin</a>, Drugs.com, January 2006</span></li><li id="cite_note-33"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-33">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.msnbc.msn.com/id/12636315">Pfizer faulted over drug trials in Nigeria</a>, msnbc.com, 2006</span></li><li id="cite_note-34"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-34">↑</a> <span class="reference-text">Chris McGreal <a rel="nofollow" class="external text" href="http://www.guardian.co.uk/medicine/story/0,,2095955,00.html">Nigeria sues Pfizer for $7bn over 'illegal' tests on children</a>, The Guardian, June 2007</span></li><li id="cite_note-35"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-35">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.boston.com/business/healthcare/articles/2007/06/05/nigeria_suing_pfizer_over_study_of_drug">Nigeria suing Pfizer over study of drug: Officials seek $7b, say some children disabled or killed</a>, Bloomberg News, June 5, 2007</span></li><li id="cite_note-36"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-36">↑</a> <span class="reference-text">Camillus Eboh <a rel="nofollow" class="external text" href="http://www.reuters.com/article/domesticNews/idUSL2585915420070725">The

Nigerian federal government has filed criminal charges against U.S.

drugmaker Pfizer alleging improper behavior in a 1996 drug trial in the

northern state of Kano in which it says 11 children died.</a>, ABUJA (<a href="http://www.sourcewatch.org/index.php/Reuters" title="Reuters" class="mw-redirect">Reuters</a>), 2007</span></li><li id="cite_note-37"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-37">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.guardian.co.uk/business/2010/dec/09/wikileaks-cables-pfizer-nigeria">WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout</a>, The Guardian, 9 December 2010</span></li><li id="cite_note-38"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-38">↑</a> <span class="reference-text"><i>Forbes</i>, March 2008</span></li><li id="cite_note-39"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-39">↑</a> <span class="reference-text">Donald G. McNeil, Jr. <a rel="nofollow" class="external text" href="http://query.nytimes.com/gst/fullpage.html?res=9901E4D81438F93AA35754C0A9669C8B63&sec=&spon=&pagewanted=print">Medicine Merchants: Patents and Patients; As Devastating Epidemics Increase, Nations Take On Drug Companies</a>, <a href="http://www.sourcewatch.org/index.php/New_York_Times" title="New York Times">New York Times</a>, July 9, 2000</span></li><li id="cite_note-40"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-40">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.all-creatures.org/saen/nj/res-fr-nj-fdah.html">Facility Reports and Information: Fort Dodge Animal Health, Monmouth Junction, New Jersey</a>, Stop Animal Exploitation NOW!, accessed October 2009</span></li><li id="cite_note-41"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-41">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.all-creatures.org/saen/il/res-fr-il-pfi.html">Facility Reports and Information: Pfizer, Inc., White Hall, IL</a>, SAEN, accessed January 2010</span></li><li id="cite_note-42"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-42">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.shac.net/HLS/exposed/inside_hls/Inside_customers.html">Inside Customers</a>, SHAC.net, accessed January 2011</span></li><li id="cite_note-43"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-43">↑</a> <span class="reference-text">Chris Halsne <a rel="nofollow" class="external text" href="http://www.kirotv.com/news/15189249/detail.html">Monkey Boiled Alive At Research Lab</a>, KIRO 7 Eyewitness News, February 2008</span></li><li id="cite_note-44"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-44">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.pfizer.com/about/leadership_and_structure/meet_executive_leaders.jsp">Pfizer Executive Leadership Team</a>, accessed January 2011</span></li><li id="cite_note-45"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-45">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://finance.yahoo.com/q/pr?s=PFE">Pfizer Profile: Key Executives</a>, <i>Yahoo Finance</i>, accessed January 2011</span></li><li id="cite_note-46"><a href="http://www.sourcewatch.org/index.php/Wyeth#cite_ref-46">↑</a> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.pfizer.com/about/corporate_governance/board_committees_charters.jsp">About Pfizer: Board Members</a>, Pfizer, accessed January 2011</span></li></ol>

</div>

<h3> <span class="mw-headline" id="External_articles">External articles</span></h3>

<ul><li>Martha Rosenberg <a rel="nofollow" class="external text" href="http://www.sott.net/articles/show/211939-Pfizer-The-Drug-Giant-That-Makes-Bank-from-Drugs-That-Can-Kill-You">Pfizer: The Drug Giant That Makes Bank from Drugs That Can Kill You</a>, Alternet, Health & Wellness, July 2010</li><li><a rel="nofollow" class="external text" href="http://www.stopanimaltests.com/f_ten_worst_ceo.asp">PETA Names the 10 Worst CEOs for Animals in Laboratories</a>, <a href="http://www.sourcewatch.org/index.php/People_for_the_Ethical_Treatment_of_Animals" title="People for the Ethical Treatment of Animals">People for the Ethical Treatment of Animals</a>, accessed December 2009</li><li>Stephanie Saul, "<a rel="nofollow" class="external text" href="http://www.nytimes.com/2007/04/10/business/media/10celebrex.html">Celebrex Commercial, Long and Unconventional, Draws Criticism</a>," New York Times, April 10, 2007</li><li>Rick Weiss, "<a rel="nofollow" class="external text" href="http://www.washingtonpost.com/wp-dyn/content/article/2006/06/13/AR2006061301528.html">'Serious Misconduct' by NIH Expert Found: Scientist Did Not Report Sending Tissues to Drug Firm and Getting Paid, Report Says</a>," <a href="http://www.sourcewatch.org/index.php/Washington_Post" title="Washington Post">Washington Post</a>, June 14, 2006</li><li>Alex Berenson, "<a rel="nofollow" class="external text" href="http://query.nytimes.com/gst/fullpage.html?sec=health&res=9C06E2D91F3EF937A35751C1A9609C8B63">End of Drug Trial Is a Big Loss For Pfizer and Heart Patients</a>", <a href="http://www.sourcewatch.org/index.php/New_York_Times" title="New York Times">New York Times</a>, December 6, 2006</li><li>Marc Kaufman, "<a rel="nofollow" class="external text" href="http://www.washingtonpost.com/wp-dyn/content/article/2005/06/30/AR2005063001419.html">FDA

Was Told of Viagra-Blindness Link Months Ago: Senator Criticizes Delay

in Alerting Consumers After Safety Officer Warned Agency About D rug</a>", <a href="http://www.sourcewatch.org/index.php/Washington_Post" title="Washington Post">Washington Post</a>, July 1, 2005.</li></ul>

<h4> <span class="mw-headline" id="Books">Books</span></h4>

<ul><li>Peter Rost, M.D. <a rel="nofollow" class="external text" href="http://www.amazon.com/exec/obidos/ASIN/193336839X/counterpunchmaga">The Whistleblower, Confessions of a Healthcare Hitman</a>", Soft Skull Press, September 2006, <a href="http://www.sourcewatch.org/index.php/Special:BookSources/9781933368399" class="internal mw-magiclink-isbn">ISBN 978-1933368399</a> (Dr. Rost is a former VP of Pfizer).</li></ul>

    
        
    
    
            
    <div id="catlinks" class="catlinks"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="http://www.sourcewatch.org/index.php/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="http://www.sourcewatch.org/index.php/Category:ALEC_Exposed" title="Category:ALEC Exposed">ALEC Exposed</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Global_corporations" title="Category:Global corporations">Global corporations</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Pharmaceutical_industry" title="Category:Pharmaceutical industry">Pharmaceutical industry</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:United_States" title="Category:United States">United States</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Human_rights_abuses" title="Category:Human rights abuses">Human rights abuses</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Animal_testing" title="Category:Animal testing">Animal testing</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Huntingdon_Life_Sciences" title="Category:Huntingdon Life Sciences">Huntingdon Life Sciences</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:International" title="Category:International">International</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:AIDS" title="Category:AIDS">AIDS</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Cancer" title="Category:Cancer">Cancer</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Agriculture" title="Category:Agriculture">Agriculture</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:Gross_Animal_Welfare_Violations" title="Category:Gross Animal Welfare Violations">Gross Animal Welfare Violations</a></li><li><a href="http://www.sourcewatch.org/index.php/Category:ALEC_Corporations" title="Category:ALEC Corporations">ALEC Corporations</a></li></ul></div></div><br />